AR061622A1 - Esteres del acido docosahexaenoico(dha), en particular el docosahexaenoato de piridin-3-il-metilo, metodo de preparacion, composicion farmaceutica que los contiene y su utilizacion en el tratamiento y prevencion de enfermedades cardiovasculares - Google Patents

Esteres del acido docosahexaenoico(dha), en particular el docosahexaenoato de piridin-3-il-metilo, metodo de preparacion, composicion farmaceutica que los contiene y su utilizacion en el tratamiento y prevencion de enfermedades cardiovasculares

Info

Publication number
AR061622A1
AR061622A1 ARP070102779A ARP070102779A AR061622A1 AR 061622 A1 AR061622 A1 AR 061622A1 AR P070102779 A ARP070102779 A AR P070102779A AR P070102779 A ARP070102779 A AR P070102779A AR 061622 A1 AR061622 A1 AR 061622A1
Authority
AR
Argentina
Prior art keywords
docosahexaenoic acid
formula
prevention
treatment
pharmaceutical composition
Prior art date
Application number
ARP070102779A
Other languages
English (en)
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37686083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061622(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of AR061622A1 publication Critical patent/AR061622A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/02—Preparation of carboxylic acid esters by interreacting ester groups, i.e. transesterification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Procedimiento de preparacion, composicion farmacéutica que lo contiene y su utilizacion. El tratamiento o la prevencion de las enfermedades cardiovasculares. Reivindicacion 1: Éster del ácido docosahexaenoico con un alcohol seleccionado de entre las vitaminas o provitaminas del grupo B, constituido ventajosamente por: el nicotinol de la formula (2), el pantenol de la formula (3) y el inositol de la formula (4), o con la isosorbida de la formula (5) o el mononitrato de isosorbida de la formula (6). Reivindicacion 2: Éster del ácido docosahexaenoico segun la reivindicacion 1, caracterizado porque se trata del docosahexaenoato de piridin-3-ilmetilo de la formula general (1).
ARP070102779A 2006-06-23 2007-06-22 Esteres del acido docosahexaenoico(dha), en particular el docosahexaenoato de piridin-3-il-metilo, metodo de preparacion, composicion farmaceutica que los contiene y su utilizacion en el tratamiento y prevencion de enfermedades cardiovasculares AR061622A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0605649A FR2902659A1 (fr) 2006-06-23 2006-06-23 Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires

Publications (1)

Publication Number Publication Date
AR061622A1 true AR061622A1 (es) 2008-09-10

Family

ID=37686083

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102779A AR061622A1 (es) 2006-06-23 2007-06-22 Esteres del acido docosahexaenoico(dha), en particular el docosahexaenoato de piridin-3-il-metilo, metodo de preparacion, composicion farmaceutica que los contiene y su utilizacion en el tratamiento y prevencion de enfermedades cardiovasculares

Country Status (38)

Country Link
US (2) US8034377B2 (es)
EP (1) EP2034999B9 (es)
JP (1) JP5053372B2 (es)
KR (1) KR101380128B1 (es)
CN (1) CN101472590A (es)
AR (1) AR061622A1 (es)
AT (1) ATE489091T1 (es)
AU (1) AU2007262958B2 (es)
BR (1) BRPI0713725A2 (es)
CA (1) CA2655570C (es)
CL (1) CL2010001123A1 (es)
CO (1) CO6150156A2 (es)
CR (1) CR10507A (es)
DE (1) DE602007010776D1 (es)
DK (1) DK2034999T3 (es)
EC (1) ECSP099039A (es)
ES (1) ES2355611T3 (es)
FR (1) FR2902659A1 (es)
GE (1) GEP20125464B (es)
HN (1) HN2008001771A (es)
HR (1) HRP20110086T1 (es)
IL (1) IL195562A (es)
MA (1) MA30584B1 (es)
MX (1) MX2009000103A (es)
MY (1) MY145985A (es)
NO (1) NO20090334L (es)
NZ (1) NZ573454A (es)
PL (1) PL2034999T3 (es)
PT (1) PT2034999E (es)
RS (1) RS51629B (es)
RU (1) RU2451672C2 (es)
SA (1) SA07280345B1 (es)
SI (1) SI2034999T1 (es)
TN (1) TNSN08527A1 (es)
TW (1) TWI389888B (es)
UA (1) UA96156C2 (es)
WO (1) WO2007147899A2 (es)
ZA (1) ZA200900334B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334536B1 (es) * 2008-04-11 2011-01-24 Universidad Complutense De Madrid Procedimiento para la obtencion selectiva de 12-hidroxi-9-cis-octadecenoato de (1,4:3,6-dianhidro-d-glucitol) utilizando lipasas inmovilizadas como catalizador.
FR2949063B1 (fr) 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
KR20130098279A (ko) * 2010-06-18 2013-09-04 엑스바이오테크, 인크. 관절염 치료
FR2963790B1 (fr) * 2010-08-11 2012-09-28 Pf Medicament Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
ES2856723T3 (es) 2010-08-23 2021-09-28 Janssen Biotech Inc Tratamiento para enfermedades neoplásicas
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN102757444B (zh) * 2011-04-29 2016-02-10 南京信诺泰医药有限公司 具有一氧化氮供体性质的苯并呋喃类化合物
FR2998479B1 (fr) * 2012-11-27 2017-04-28 Pf Medicament Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
WO2016024283A1 (en) * 2014-08-12 2016-02-18 Praj Industries Limited Process for the preparation of triglycerides of epa and dha
US10441087B2 (en) 2015-02-24 2019-10-15 Sleep Number Corporation Mattress with adjustable firmness
EP3582813A4 (en) 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
CA3052206A1 (en) * 2017-02-20 2018-08-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hydrogen sulfide and/or nitrite in the treatment and prevention of atrial fibrillation
CN110950881A (zh) * 2018-09-27 2020-04-03 中国科学院上海药物研究所 一类三环类似物、其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL133049C (es) 1966-02-24
JPS5967263A (ja) 1982-10-07 1984-04-16 Terumo Corp ペンタエン高級脂肪酸ピリジルアルコ−ルエステルおよびその製法
JPS5967264A (ja) 1982-10-08 1984-04-16 Terumo Corp 血小板凝集抑制剤
WO1984001899A1 (en) 1982-11-16 1984-05-24 Georges Motschan New utilization of a unique vitamin or a combination of various vitamins
JPS6034947A (ja) * 1983-08-05 1985-02-22 Terumo Corp ドコサヘキサエン酸誘導体およびそれを用いた血小板凝集阻止剤
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
US5760081A (en) 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
EP0823897B1 (en) 1995-05-01 2004-07-28 Scarista Limited Nicotinic acid esters and pharmaceutical compositions containing them
IL118092A0 (en) 1995-05-03 1996-09-12 Smithkline Beecham Plc Antibacterial compounds their preparation and pharmaceutical compositions containing them
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
AUPQ480399A0 (en) 1999-12-22 2000-02-03 Commonwealth Scientific And Industrial Research Organisation Unsaturated fatty acids and their uses in therapy
DK1157692T3 (da) 2000-05-22 2006-02-06 Pro Aparts Investimentos E Con Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
ITMI20022511A1 (it) * 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
WO2004091603A1 (fr) * 2003-04-07 2004-10-28 Clinigenetics Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
EP1466597A1 (en) * 2003-04-07 2004-10-13 Clinigenetics Use of dha esters to control or prevent cardiovascular diseases
CN1774179A (zh) 2003-04-17 2006-05-17 贝林格尔.英格海姆国际有限公司 供孕妇用的多种维生素及矿物质补充品

Also Published As

Publication number Publication date
ES2355611T3 (es) 2011-03-29
US8034377B2 (en) 2011-10-11
FR2902659A1 (fr) 2007-12-28
CR10507A (es) 2009-02-05
RU2008152248A (ru) 2010-07-27
SI2034999T1 (sl) 2011-02-28
TW200811108A (en) 2008-03-01
NO20090334L (no) 2009-03-04
MX2009000103A (es) 2009-01-23
TWI389888B (zh) 2013-03-21
PT2034999E (pt) 2011-01-19
PL2034999T3 (pl) 2011-05-31
SA07280345B1 (ar) 2011-01-15
JP2009544576A (ja) 2009-12-17
ATE489091T1 (de) 2010-12-15
MA30584B1 (fr) 2009-07-01
KR101380128B1 (ko) 2014-04-11
ECSP099039A (es) 2009-02-27
NZ573454A (en) 2010-10-29
RS51629B (en) 2011-08-31
US20110237613A1 (en) 2011-09-29
IL195562A0 (en) 2009-09-01
UA96156C2 (ru) 2011-10-10
DE602007010776D1 (de) 2011-01-05
CA2655570A1 (en) 2007-12-27
CA2655570C (en) 2015-09-08
HN2008001771A (es) 2011-01-24
WO2007147899A2 (en) 2007-12-27
AU2007262958B2 (en) 2011-10-27
DK2034999T3 (da) 2011-01-24
EP2034999B9 (en) 2011-03-09
MY145985A (en) 2012-05-31
JP5053372B2 (ja) 2012-10-17
CO6150156A2 (es) 2010-04-20
AU2007262958A1 (en) 2007-12-27
RU2451672C2 (ru) 2012-05-27
ZA200900334B (en) 2009-12-30
EP2034999B1 (en) 2010-11-24
US8227479B2 (en) 2012-07-24
EP2034999A2 (en) 2009-03-18
BRPI0713725A2 (pt) 2012-10-30
HRP20110086T1 (hr) 2011-03-31
US20090312354A1 (en) 2009-12-17
CN101472590A (zh) 2009-07-01
CL2010001123A1 (es) 2011-03-25
KR20090024794A (ko) 2009-03-09
IL195562A (en) 2012-06-28
GEP20125464B (en) 2012-04-10
WO2007147899A3 (en) 2008-03-13
WO2007147899B1 (en) 2008-05-02
TNSN08527A1 (en) 2010-04-14

Similar Documents

Publication Publication Date Title
AR061622A1 (es) Esteres del acido docosahexaenoico(dha), en particular el docosahexaenoato de piridin-3-il-metilo, metodo de preparacion, composicion farmaceutica que los contiene y su utilizacion en el tratamiento y prevencion de enfermedades cardiovasculares
NZ741022A (en) Flavonoid compositions and methods of use
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
CO6470839A2 (es) Composiciones farmacéuticas que contienen epa y un agente cardiovascular y métodos de emplearlas
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
CO6501136A2 (es) Composiciones que comprenden una mezcla de aceite de ácido graso y un tensoactivo, y métodos y usos de las mismas
CR20120167A (es) Conjugados de niacina y ácidos grasos y sus usos
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
CL2011002745A1 (es) Compuestos derivados de acidos grasos poliinsaturados; metodo de preparacion; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de trastornos cardiovasculares, metabolicos e inflamatorios, tales como, artritis reumatoide, aterosclerosis, diabetes, dislipidemia, entre otras.
CU20130063A7 (es) Proceso de producción de depsipéptidos cíclicos
MX2013010076A (es) Composiciones y metodos que comprenden c16:1n7 palmitoleato.
BRPI0515209A (pt) compostos, composição cosmética, usos de uma composição e composição farmacêutica
CO6620068A2 (es) Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi)
BR112015018270A2 (pt) composições que compreendem 15-ohepa e métodos de uso das mesmas
EP2257161A4 (en) AHCY HYDROLASE INHIBITORS FOR THE TREATMENT OF HYPER-HOMOCYSEINEMIA
HRP20201221T1 (hr) Sastavi omega 3 masnih kiselina za liječenje bolesti koje uključuju štete nastale u živčanom sustavu
CL2015003596A1 (es) Formulación de liberación modificada
GB2544204A (en) Preparation and composition of medium chain triglycerides containing substantial amount of lauric acid
AR085049A1 (es) Uso de al menos un coproducto de la industria del refinamiento de aceites vegetales para obtener un insaponificable total purificado de aceite vegetal
PE20160866A1 (es) Extracto vegetal con esteres de sacarosa como principio activo para su uso en composiciones cosmeticas, dermatologicas o nutricosmeticas
PH12016501111A1 (en) Composition comprising ferric saccharate and high concentrations of microencapsulated lc-pufa with a reduced off taste
ES2669311T3 (es) Incremento de la biodisponibilidad de los ácidos hidroxicinámicos
CO6390033A2 (es) Ácido graso pliinsaturado y éster de diol como agente anti-acné
BR112017002475A2 (pt) composições e método cosmético não terapêutico

Legal Events

Date Code Title Description
FC Refusal